Proof of Concept on Functionality Improvement of Mesenchymal Stem-Cells, in Postmenopausal Osteoporotic Women Treated with Teriparatide (PTH1-34), After Suffering Atypical Fractures
| Autor: | Gabriel Dorado, José Manuel Quesada-Gómez, Cristina Navarro-Valverde, Antonio Casado-Díaz, M.J. Montoya, Mercè Giner, Adolfo Diez-Perez |
|---|---|
| Přispěvatelé: | Ministerio de Economía y Competitividad (España), Instituto de Salud Carlos III, European Commission, Junta de Andalucía, Ministerio de Ciencia e Innovación (España) |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Homeobox protein NANOG medicine.medical_specialty Stromal cell Endocrinology Diabetes and Metabolism Biopsy Osteoporosis Primary Cell Culture 030209 endocrinology & metabolism Proof of Concept Study 03 medical and health sciences 0302 clinical medicine Endocrinology SOX2 Bone Marrow Internal medicine Teriparatide Adipocytes Medicine Humans Orthopedics and Sports Medicine Cells Cultured Cellular Senescence Osteoporosis Postmenopausal Aged Cell Proliferation Osteoblasts Bone Density Conservation Agents business.industry Mesenchymal stem cell Remission Induction Osteoblast Cell Differentiation Mesenchymal Stem Cells medicine.disease medicine.anatomical_structure Female 030101 anatomy & morphology Bone marrow business Osteoporotic Fractures medicine.drug |
| Zdroj: | Digital.CSIC. Repositorio Institucional del CSIC instname |
| ISSN: | 1432-0827 |
| Popis: | Osteoporosis long-term treatment with nitrogen-containing bisphosphonates, has been associated with uncommon adverse effects, as atypical femoral fractures (AFF). Thus, treatment with teriparatide (TPTD; fragment of human parathyroid hormone; PTH1−34) has been proposed for such patients. Besides its anabolizing effect on bone, TPTD may affect stem-cell mobilization and expansion. Bone marrow mononuclear cells (BMMNC) were isolated from five women that had suffered AFF associated to bisphosphonate treatment, before and after 6 months of TPTD therapy. The presence of mesenchymal stromal cells (CD73, CD90 and CD105 positive cells), gene expression of NANOG, SOX2 and OCT4, proliferation, senescence and capacity to differentiate into osteoblasts and adipocytes were analyzed. After TPTD treatment, BMMNC positive cells for CD73, CD90 and CD105 increased from 6.5 to 37.5% (p Supported by Grants AGL2013-45110-R of “Ministerio de Ciencia e Innovación” (MICINN); PI081692 and PI15/01857 “Red Temática de Investigación Cooperativa en Envejecimiento y Fragilidad” (RETICEF) and CIBER “Fragilidad y Envejecimiento Saludable” (CIBERFES) of “Instituto de Salud Carlos III” (ISCIII), “Ministerio de Economía y Competitividad” (MINECO) and European Union (EU); and “Ayudas de Intensificación de la Investigación” and “Grupo CTS413” of “Junta de Andalucía”, Spain. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink